{
  "id": 7721003,
  "title": "Barclays upgrades Alvotech stock rating on FDA approval outlook",
  "url": "https://urgent.news/2026/09/16/barclays-upgrades-alvotech-stock-rating-on-fda-approval-outlook",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-16T06:10:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/barclays-upgrades-alvotech-stock-rating-on-fda-approval-outlook-93CH-4902908"
  },
  "original_language": "en",
  "account": "Barclays has upgraded Alvotech SA's stock rating from Underweight to Overweight, citing an optimistic outlook following the FDA's approval of their biologics license applications. The pharmaceutical company's shares have soared 39% over the past six months, currently trading at $5.02, though they still lag behind their 52-week high of $9.25. The upgrade is contingent on Alvotech's successful resubmission of biosimilars, including Simponi, Simponi Aria, Eylea, and Prolia/Xgeva, which the FDA has acknowledged as complete responses and aims to review by December 4, 2026. The FDA also completed a routine inspection of Alvotech's Reykjavik facility in May, formally closing it in July with a Voluntary Action Indicated classification, indicating the facility remains an FDA-approved manufacturing site. Alvotech has reaffirmed its fiscal 2026 revenue target of $650 million to $700 million, expecting a significant ramp-up in the third and fourth quarters, with milestone revenue potentially reaching $250 million. Barclays projects EBITDA could reach $270 million to $290 million next year, representing substantial upside from the company's $75.73 million EBITDA in the previous twelve months. The stock appears slightly undervalued, with a Fair Value of $5.37. Alvotech's second-quarter 2026 earnings reported a revenue of $106 million and an adjusted loss of 5.4 cents per share, falling short of Wall Street's expectations, partly due to manufacturing disruptions related to facility upgrades. BofA Securities initiated coverage on Alvotech with a buy rating and a price target of $7.00, expressing optimism about the company's long-term prospects.",
  "summary": null,
  "key_points": [
    "Barclays upgrades Alvotech stock rating to Overweight",
    "FDA approval outlook for biosimilars drives optimism",
    "EBITDA projected to reach $270 million to $290 million next year"
  ],
  "editors_take": "Barclays' upgrade of Alvotech's stock rating to Overweight signals increased confidence in the company's prospects following FDA approval developments, suggesting potential for substantial upside in revenue and EBITDA.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}